ENDRA Life Sciences (NDRA) to Release Quarterly Earnings on Thursday

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $0.10 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.14. On average, analysts expect ENDRA Life Sciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Get ENDRA Life Sciences alerts:

ENDRA Life Sciences Price Performance

ENDRA Life Sciences stock opened at $4.44 on Tuesday. The firm has a market capitalization of $5.64 million, a P/E ratio of -0.54 and a beta of -0.05. ENDRA Life Sciences has a 1-year low of $2.96 and a 1-year high of $9.85. The company’s 50-day moving average is $4.87 and its 200 day moving average is $4.60.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Ascendiant Capital Markets cut their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Weiss Ratings raised shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $25.00.

View Our Latest Research Report on ENDRA Life Sciences

About ENDRA Life Sciences

(Get Free Report)

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.

Read More

• Five stocks we like better than ENDRA Life Sciences
• SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
• 3 Dividend Champion Utilities for a Market That Can’t Sit Still
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.